Patient Leaflet Updated 24-Nov-2025 | Baxter Healthcare Ltd
Metronidazole 500 mg / 100 ml Intravenous Infusion
Metronidazole 500mg/100ml Intravenous Infusion
1. What Metronidazole 500mg/100ml is and what it is used for
2. What you need to know before you use Metronidazole 500mg/100ml
3. How to use Metronidazole 500mg/100ml
4. Possible side effects
5. How to store Metronidazole 500mg/100ml
6. Contents of the pack and other information
The active ingredient in your medicine is metronidazole. It is an antimicrobial agent (an agent that kills micro-organisms or suppresses their multiplication and growth).
Your medicine contains metronidazole 500mg per 100ml (5 mg per ml). This is a sterile solution for intravenous infusion free from bacterial endotoxin (substances causing fever reactions).
This medicine is used when oral medication is not possible, for the prevention and treatment of infections caused by certain species of bacteria. It is used in adults and children for:
Metronidazole 500mg/100ml must only be used under medical supervision.
If you need any further information on your condition, please ask your doctor.
Tell your doctor immediately and stop taking metronidazole if you develop:
Talk to your doctor before using Metronidazole 500mg/100ml:
Your doctor may want to carry out some tests if you receive this medicine for more than 10 days.
Your doctor may want to carry out some tests if you receive this medicine for more than 10 days.
Certain medicines are known to change the normal effect of this infusion. Certain medicines can have their effect changed by this infusion. These medicines should not be used at the same time as Metronidazole 500 mg/100ml Intravenous Infusion. Please tell your doctor if you are taking, have recently taken or might take any of the following medicines:
Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Do not drink any alcohol while receiving your medicine, and for 72 hours afterwards. This might cause unpleasant side effects, such as feeling sick and vomiting, abdominal pain, hot flushes, palpitations, and headache.
This medicine should be avoided during pregnancy or breast-feeding unless your doctor considers it essential.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
You should not drive or use machines while being treated with this medicine.
This medicinal product contains 310 mg sodium per dose. To be taken into consideration by patients on a controlled sodium diet.
Your doctor will decide how much you need and when it will be given to you.
Each bag is one dose and will be administered through a plastic tube into a vein using a drip. It will be given at a rate of approximately 5 ml/minute (equivalent to the infusion of one bag over 20 to 60 minutes). As soon as possible after the infusion has been completed, your treatment will be continued using oral medication. Your doctor will decide when you can start to take oral medication instead of the drip.
The amount you will be given depends upon
The preventive treatment duration will be short and mostly limited to the post-operative period (24 hours but no more than 48 hours).
Adults will usually receive
A 500 mg dose (1 bag) will then usually be repeated every 8 hours as necessary.
Children less than 12 years will receive a smaller dose which is calculated from their body weight as a single dose of 20-30mg/kg given one to two hours before surgery
Newborn infants born prematurely (gestational age less than 40 weeks) will receive one single dose of 10 mg/kg body weight prior to surgery.
This medicine will be used for the treatment of established infections when you are unable to take the medicine by mouth.
Adults will usually receive a single daily dose of 1000 to 1500 mg (2 to 3 bags) or 500 mg (1 bag)every 8 hours.
Children more than 8 weeks to 12 years of age will receive a smaller dose which is calculated from their body weight as
Newborn infants (less than 8 weeks old) will receive one single daily dose of 15mg/kg of body weight or 7.5mg/kg every 12 hours.
Newborn infants born prematurely (gestational age less than 40 weeks) will have their level of metronidazole in blood controlled after a few days of therapy as accumulation of the drug substance in the blood might occur during the first week of life.
Metronidazole will be administered to the Elderly with caution, especially where high doses are required. Your doctor will modify your dose as required.
There is no need to adjust the dosage if you have problems with your kidneys. Your doctor will most probably not adjust the dosage of your medicine if you are undergoing peritoneal dialysis. Your doctor can however take the decision to reduce the dosage of metronidazole if excessive levels of metabolites are found in your blood.
If you are undergoing haemodialysis your doctor will re-administer your medicine just after haemodialysis.
Your doctor will reduce the dosage. Your doctor will at the same time monitor the level of metronidazole in your blood.
Duration of treatment for ongoing infections is usually 7 to 10 days.
Depending upon your clinical condition and results of bacteriological assessment, your doctor may decide to prolong the treatment. This is intended to eradicate infections from parts of your body where the anti-infective metronidazole has difficulties to access or where self-recontamination is possible.
If you have received more infusion than you should, the following symptoms could appear:
No symptoms developed where too much of this medicine is given to newborn infant born prematurely.
Please inform your doctor immediately if any of these symptoms occur.
In the event of accidental over-infusion, your doctor will stop the infusion. Your doctor will take the appropriate measures according to the symptoms you have developed.
If you have any further question on the use of this medicinal product please ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following severe side effects can occur rarely (may affect up to 1 in 1,000 people):
Not known (frequency cannot be estimated from the available data):
If you experience any of these severe side effects, please tell your doctor immediately. The doctor will stop the infusion.
Tell your doctor if any of the following side effects occur:
If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label after Exp:. The expiry date refers to the last day of that month. You will not be given this medicine if this date has passed.
Keep container in the outer carton in order to protect from light.
Do not remove the unit from overwrap until ready for use.
Do not use if the solution is not clear, or if the unit is damaged in any way.
Discard any unused portion.
This leaflet does not contain all the information about this medicine. If you have any questions or are not sure about anything, ask your doctor or nurse.
It is an isotonic solution.
The active substance is Metronidazole. Each 100 ml consists of: Metronidazole 500 mg
The other inactive ingredients (excipients) are Disodium phosphate dodecahydrate, Citric acid monohydrate, Sodium chloride and Water for injections.
It is a clear solution for infusion intended for intravenous administration.
The solution is in 100ml polyolefin/polyamide transparent plastic containers protected by a transparent plastic overwrap.
The pack size is: 20 x 100 ml, 50 x 100 ml and 60 x 100 ml.
Marketing Authorisation Holder:
The company responsible for the product (also known as the marketing authorization holder) is:
Manufacturer:
The product may be made by:
This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
United Kingdom (Northern Ireland) Metronidazole 500mg/100ml Intravenous Infusion
Denmark Metronidazol “Baxter” Viaflo Infusionsvæske, opløsning
Norway Metronidazol Baxter Viaflo 5 mg/ml Infusjonsvæske, oppløsning
Iceland Metronidazol Baxter Viaflo 5 mg/ml Innrennslislyf, lausn
The leaflet was last revised in August 2024
CB-30-03-072
Caxton Way, Thetford, Norfolk, IP24 3SE, UK
0800 0260516
https://medinfo.baxterhealthcare.co.uk
https://www.baxterhealthcare.co.uk/
0800 028 9881